Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
And welcome to XVIVO's earnings call for the third quarter of 2024. On the first slide, today's presentation includes those who are sitting in the same room: Christoffer Rosenblad, CEO, and beside me, Kristoffer Nordström, CFO of XVIVO Perfusion. And with that, we turn to slide two. The Q3 financials at a glance, and I'm proud and happy to report that Q3 shows improvement on top line as well as EBITDA compared to the same quarter last year. Even though we have continued and will continue to invest in the organization for future growth. Sales came in at 191 million, representing a 41% organic growth, and EBITDA improved to 21%. The growth for the thoracic sector is mainly coming from higher activity during the quarter. Another growth driver we see in this quarter is the US heart trial, where we have seen very high interest to join the trial as well. As well as very high activity in the trial during the summer months. Kristoffer Nordström, our CFO, will delve into the details of sales, gross margin, EBITDA, and the financial figures later in the presentation. So with that, we go to the next slide, which is slide three. And we see a similar picture in the YTD numbers. Key takeaway from the first nine months is that growth is still mainly coming from increased activity in existing customers and a stronger market for hearts and lungs. We see a very high interest from new customers, especially after I mentioned in April that we are gradually starting to see conversions to sales from these new customers. And we can also conclude that sales from products are picking up faster than sales from services. Even though we have a fantastic service offering with very good quality regarding EBITDA. Even though we have invested heavily in mainly commercial and field force, we can now see that the revenue model is scalable. In other words, sales are converted to cost to achieve economies of scale on gross margin as well as EBITDA level. Lastly, and most importantly, it is worth mentioning that the projects are progressing according to plan. The heart project is on time and on budget. The Production Capability Capacity project, where we invest to scale up volumes to ten times today's volume for disposables, is running in line with communicated timelines. The first milestones for Kidney Assist Transport and Liver Assist have been completely achieved. And we have production volume to satisfy current market demand. As communicated earlier, the full-scale production of disposables for heart, liver, and kidneys is estimated to be completed at the end of Q2 2025. But as I said, we deem we have enough volumes to meet the needs for the next year. And with that, we will go into the highlights of the quarter. So first, our business overview on slide four, which we can actually turn directly to slide five. And we will start with heart and end uses in heart. Um, this slide shows the summary of the heart trial that was presented at the ISHLT conference in April in Prague this year, and I have shown it before. But we start with those key takeaways, and the reason I show it again is that it's very good data, which we want to repeat. And number one is that this is, to our knowledge, the first randomized controlled trial with a superiority design in heart and lung transplantation ever performed, which shows the confidence the clinicians have in integrating our technology with the HOPE group. In other words, pumping with the technology showed a 61% improvement in PGD versus the control group, which is highly important given that PGD is the leading cause of early and late mortality in heart transplantation. Thirdly, and also very importantly, all harvested organs were deemed transplantable after perfusion. This is important to highlight since cold perfusion offers a safety advantage during transportation. And then we go over to slide six and the news during the quarter for heart transplantation that was presented in The Lancet during the quarter. Following this publication, we are now more convinced than ever that this product has the ability to change the paradigm of heart transplantation. And I want to highlight two key takeaways. And the first. The first one is that when we adjusted for minor differences between the 15 trial sites, we saw that the results were even better. We saw that the primary endpoint had a 49% risk reduction. Uh, that was well within the statistical significance threshold. The other very interesting fact we see when we dig into the data is that during the seminal analysis of PGD, we saw that severe PGD showed an even higher risk reduction with 76% for the HOPE group, i.e. Pumped with exhibited technology versus the control group. And this is very important and very encouraging since severe PGD is highly linked to mortality after transplantation; some sources say that severe PGD is associated with nearly an eightfold increase in the probability of one-year mortality. So, it is obvious that with this new knowledge. We look forward to the one-year follow-up of the data, including the one-year survival data points that will be presented during ISHLT in Boston, and that will take place in April 2025. And with that, we turn to slide seven. We have discussed DCD hearts before, and now we will increase our efforts. To start with, we know that the portion of the donor pool coming from DCD is comparatively large in some countries and is growing rapidly. And if you want to substantially increase the number of transplants, we need to prove that DCD hearts can be transplanted in a safe, cost-efficient, and practically feasible way with good patient outcomes. And the study we are now running in Benelux, Belgium, and the Netherlands is designed to show exactly that. The experience we have from liver and kidney HOPE shows very good clinical outcomes. That shows very good clinical outcomes. So, the concept is proven. We have also seen in preclinical settings on hearts that using the Ex-vivo heart technology on DCD direct procurement shows very good results. And we have now reported, or rather, Dr. Filip Rega from Leuven has reported the first three DCD cases and they had very good and encouraging results. So, this study, along with the regulatory study in the US, is designed to demonstrate the safety and efficacy of DCD hearts. The company hopes and believes that we will have good evidence when the two studies are concluded. Besides this, I also want to mention that the Pegasus, or Pegasus in English, study by Professor LeBreton is progressing. The study is conducted with transatlantic flights on commercial airlines to demonstrate that transport exceeding 12 hours is safe and feasible in a practical setting. When this trial is concluded, we believe that it can revolutionize heart transplant logistics, providing the first proof that our technology can enable both patient benefits and cost benefits for healthcare systems around the world. With the body of evidence pointing towards the XVIVO heart technology to become the gold standard in the future, the company is working towards that goal. However, until further evidence is presented and accepted, the EU launch will still target approximately 50% of donated hearts that are either from older donors, have typically long transplantation times, or involve complicated implant procedures that will mandate the longer out-of-body time for the donated heart. But that being said, that's the current hypothesis for the EU launch. But we believe that over time, this has the ability to become the gold standard. In other words, all hearts should be transported on the XVIVO device. And going from the heart, we move on to the next slide, which is slide eight, and we delve into the lungs. The body of evidence for lung support is strong and is gaining acceptance as a tool to safely increase the number of lung transplants and decrease waitlist mortality. So without going into details, we can now conclude that LP is a clinically proven, accepted method to reduce waiting list mortality with good clinical outcomes. And with that, I go into the next slide, which is slide nine. And this is to show that if we have good clinical evidence over time, it translates to good performance on the market. And so we see that the LP growth is high, especially in the US, where we see a doubling this Q3 versus last. Um, and there are many factors behind the growth we see. For example, the pressure from the American political system to increase the number of transplants has a positive impact on perfusion for lungs. We also see the hub models or centralized perfusion models helping to drive growth. And the other trend we see is that with the positive RCT and more feet on the ground, we see an increased interest for EVLP. And this interest is directly translated into an increased number of lung transplants and hence more patients getting a chance of a lung transplant. So key takeaways from the two lung slides are that innovative products with good clinical outcomes sooner or later translate into increased activity and shorter waiting lists for transplant patients in need of a new organ. And with that, we go to slide number ten, where we have even more exciting news and events. And this is the liver product. We have Liver Assist, where we see the same level of evidence or almost better, and where we deem our Liver Assist HOPE technology is now clinically proven. During the last year, we have seen more than 20 publications on the Liver Assist technology, showing improved patient outcomes on both DBD and DCD grafts after transplantation. I choose to highlight three of those publications, and they are listed on this slide. And the first one at the top, I would say, is the most important, where we see 1200 livers using HOPE in a real-world setting trial, with results showing a five-year graft survival at 91% in the HOPE group versus 81% in standard care. In the publication, it was stated that HOPE treatment now reached IDEAL Stage 4, which means, in more everyday English, that it's proven in a real-world setting and not only in clinical trials. And this is.
The.
Let's say, the highest level of support, and this supports the implementation of Liver Assist. And HOPE could become routine practice for liver transplantation. And that's something we work with in liver to get to the gold standard position where we have regulatory approval for Liver Assist. Secondly, we have very encouraging long-term data, showing that the more marginal donated livers have a higher need for Liver Assist and HOPE. Published data on extended criteria DCD shows that the five-year outcome of 87% organ survival, which is very, very strong in itself. But if compared to, for example, the expected one in the standard care group. In the publication mentioned above, using standard care resulted in only 81% organ survival for good livers. But the result becomes evident when we compare the 87% graft survival in the Liver Assist group to the control group, where the result was 52%. The last publication I want to highlight, which is important if we aim to become the gold standard in liver transplantation, is the recent Lancet publication. It shows that the liver can be safely perfused after 20 hours, eliminating the need for nighttime liver transplants. And this is again a great example of how we can improve graft survival and also enhance work-life balance for our customers. Lastly, as stated earlier, the production scale-up by ten times is progressing according to plan. We reached our first milestone and we deem that we have enough production capacity to bridge the gap until next year when we will have full-scale production running. And with that, we go to slide 11, which is the last slide on the quarterly business update. And that's the recent acquisition of FlowHawk, which is a unique communication platform for the transplant process. The background is that with an increased number of organ offers in the US, the complexity for OPOs and Transplant Centers has increased dramatically. To ease that burden, a HIPAA-compliant, easy-to-use communication tool is needed and the best solution on the market is FlowHawk. FlowHawk is already used today by leading transplant clinics, and with combined forces. We will strengthen the offer to clinics and OPOs in the future, and we will also, over time, integrate our product remote monitoring system into FlowHawk for a seamless customer experience. So we believe this is a very important strategic step for ex vivo to be a provider of easy-to-use products for our customers in the future. And with that, we will go into our clinical pipeline and proceed to slide 12. And then we can skip right away to slide 13 for a regulatory review. And again, I will say that nothing has changed since the last time we met. So I will repeat what I said in July in the US. The heart trial is progressing according to plan and our clinical team in the US is working very hard to include all clinics in the trial. The interest is very high. I would say extremely high to be part of the trial, and we are doing our utmost to make sure that we can meet that interest from U.S. clinics. Clinics. We have approval for up to 26 sites. We have activated 13 sites and, as we speak, 12 are including patients into the trial. As also mentioned before, in Europe, we have submitted our technical documentation for review according to our timetable. We are aiming for a CE mark in Europe at the end of this year, and it is important to mention that we cannot fully influence the review timeline. The good news is that we have a notified body lined up and they've been very responsive, even though they have a very high workload on MDR. Security in the timeline we still face is how quickly the EMA, European Medicines Agency, and the Swedish MPA can handle the review. We have really done what we can to submit our files on time, both for product and clinical files with very good quality. However, I want to emphasize that this is slightly beyond our control. In Australia and New Zealand, as I mentioned before, we have high usage of the product. The regulatory approval will be pending upon the CE mark in Europe. So, we then go to the liver. We have previously reported that Liver Assist has been granted breakthrough device designation by the FDA. And this means that we gain a faster route through the FDA PMA process. I also want to emphasize the quality stamp, indicating that the products are innovative and meet a market need. We have invested in the organization to run the study and prepare the FDA documentation. We are in close contact with the FDA regarding their final IDE application, which we aim to submit before the end of this quarter. And with the clinical and regulatory review, we go over to, I hand over to my CFO, Kristoffer Nordström, who will present the financial performance during the quarter and the year so far.
Yes. Thank you. Christoffer. Yes. So, in Q3, ex vivo presented yet another solid quarter. Net sales came in at 198 million, representing an organic growth of 41%. Overall, the gross margin was 75%. That's 2 percentage points better than last year due to product mix. Uh, continued improvements on EBIT and EBITDA. So Ebit in Q3, adjusted for M&A costs of 5 million SEK, was 13% versus 10% last year, mainly driven by increased sales and stronger gross margins from our thoracic business area. Adjusted EBITDA in Q3, with similar adjustments for M&A costs, was 21% versus 19% last year. Looking at the year-to-date numbers, we are close to 600 million SEK in sales, representing a growth of 36% in local currencies. Um, and a nice trend on EBIT and EBITDA as well. So EBIT was 13% and EBITDA was 22%. We'll look a little bit deeper into each business area. So, next slide here starts with thoracic. As you know, it was yet another good quarter with sales coming in at 141 million SEK, the same number as the previous quarter. Actually, on the dot, which means that thoracic kept the train rolling, so to say. Also during the summer months, organic growth for disposables in Q3 was strong at 54%. Main drivers. Kristoffer mentioned before, EVLP in the US specifically, where we saw LP sales grow 100 to 110% in value versus last year. The momentum for LP sales throughout 2024, as you know, has been very tangible year to date. We have grown our LP business in the US as an example, achieving an 80% increase in terms of units sold versus last year. During the year, we have activated new transplant clinics and, most recently in the third quarter in the US, a very prominent IPO, which we are very excited about. We also had one HBS sale in Germany this quarter. On the sales side, it's also great to share that we continue to see good sales from heart treatment reaching 19 million SEK in Q3, primarily from the revenue under our US trial where we have CMS reimbursement in place. Gross margin on disposables in Q2 was 8,085% and in line with the previous years. Very good, 8.085%, and in line with previous years. Moving over to ABDOMINAL net sales: 39 million SEK, which is 8 million SEK less than sales in Q2. As communicated during the Q2 earnings call, we expected somewhat weaker transplant activities over the summer months, especially in Europe, which is still the home turf for our ABDOMINAL business area. The weaker sales in ABDOMINAL can primarily be explained by the summer effects, so to say. Organic growth in disposables was 13%. Uh, the mix between liver and kidney. We recognize that ratio from previous quarters as well. So about one third of our sales are kidney-related and two thirds are liver sales. Kidney transport revenue exceeded 10 million and we have reached 35 million year to date. Christoffer mentioned it, but I will emphasize this in terms of kidney transport supply: we are now in a position where we can meet current customer demand but also start approaching new customers. Focus for Q4 and beyond is to continue scaling up the commercial organization and also to start acquiring clinical data on US patients and donors to continue building clinical evidence supporting HOPE in the US. In 2024, for example, we had a good start, with physicians presenting at two transplant conferences. Um, both presentations on US data indicate improved delayed graft function in extended criteria donors using HOPE versus static cold storage. So it will be important for us to continue to build clinical evidence. And also in the US, this will lead us to high market penetration and to establish reimbursement over time. Gross margin was 62% on disposables versus 61% last year. Moving over to services, our third business area, sales in Q3 amounted to 18 million from 96 recovery cases. This represents a decrease in sales, actually -7% versus last year. Um, during Q4. Sorry. Throughout 2024. If you take the bigger picture into account, we have reorganized our commercial organization in the US. As you know, our significant growth within EVLP has shifted some focus away from this business area. And moving into 2024, we need to start organizing ourselves better around services and in a more focused way. We have continued to strengthen our recovery quality program in 2024. We take a lot of pride in that, and we receive a lot of positive customer feedback. And now we have an opportunity to integrate our FlowHawk platform into the customer offering, starting in Q4. And this will give us an even stronger service offering going into 2025, that's for sure. Um, I also want to mention another initiative that we will look into, and that is to see if we can start to include our service, our organ recovery service model, into our clinical trials. So our heart centers and also, eventually, our upcoming liver trial. There is a great interest in combining our products with our service model. But of course, we would like to have the sites trying that before the product is commercially launched, hence already within the trial. So that is something we will investigate moving into 2024 as well, and into 2025 as well. Moving over to my two last slides. So, EBITDA stood at 21% for the quarter. I mean, we have a continued positive trend in the rolling 12. We're at 20%. So that trend develops nicely. We have stated it before. You know, our ambition is of course to continue improving EBITDA year on year. But we will do that step by step because we also want to invest heavily in this organization so we can grasp the market opportunities, yet still improve our profitability. Um, I think that is it. On that slide. Moving over to my last slide. So cash flow and financial position. Q3 once again, cash positive from operating activities, plus 23 million SEK. Investments primarily in our US clinical trials amounted to 41 million SEK. That leads us to a total cash flow of around -21 million. Uh, sorry. Uh, sorry. We ended this quarter with a solid cash position of 450 million SEK, and this was everything for me. I will hand the word over to Christoffer again and look forward to Q&A when we wrap up.
Thank you so much. The last couple of slides are on the outlook, and as always, I will start with the long-term outlook. Um, because it's important to remember why we're here. The demand for transplants is ten times higher than today's supplies. And that's the whole reason for XVIVO being a company and existing. It's also interesting to mention that the sales value of machine perfusion versus cold static storage is around ten times the value. So, we're looking at a market that will be much larger in the future than the one we see today. The machine perfusion service model has proven to increase the number of organs used for transplantation. And I think you've seen a lot of that proof today in this presentation. I also want to mention that XVIVO has unique, innovative, and world-leading products on the market or in the R&D pipeline, which we want to bring to market as soon as we can. With the recent acquisition of FlowHawk and superior clinical results for our products, we have also established a long-term goal to be sustainable for the community as a whole. We aim to build a sustainable transplant process for patients. In other words, better access to organs at a higher survival rate. We want to offer our customers a sustainable work-life balance. That is not always the case right now. We also want to offer sustainable economics for the healthcare system, and by reducing the use of private jets, we believe we can foster a sustainable future for the planet and environment as well.
And.
With that, we go over to a slightly shorter outlook, which primarily focuses on 2025. The first two points are important as we will continue to invest in commercial and organizational capabilities that can handle both growth and high growth. Especially now, as we have two product launches. Its transport in the United States and Europe. Currently ongoing. And then, as soon as we have more product visibility, we will launch the Heart device in Europe. If we look in more detail at the product line, it means that we have seen significant interest for lungs. There is a great interest from customers to start ex vivo EVLP programs, and we will invest to capture that opportunity. Continue to do that. Regarding the heart. The 2025 guidance is that we will launch our products in Europe and the Pacific. We will actually start to investigate if we can launch them in Canada as well. And we will continue to build the US regulatory and clinical file during the next year. Based on the good data and the high interest received from the clinical trial in the US. Um.
For uh.
For liver. We can see, and you've seen it today, that excellent clinical data has been published. And we will invest in commercial capabilities to capture the opportunity. We will mainly invest in Europe, and we also aim to start the clinical trial in the US next year, pending ID approval by the FDA. Now, with kidney production up and running, we will turn our focus to commercial capabilities and to building our clinical file. And lastly, we will integrate FlowHawk into our offering and continue to improve the service offering. That will be very important for our heart launch in the United States. So with that, a shorter-term outlook, we will say thank you for listening today. And we open up the line for questions.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ulrich Trattner from Carnegie. Please go ahead.
Hi, Christoffer and Kristoffer. Um, I have a few questions on my end. And perhaps starting off with extraordinary growth in lung and EVLP in the US, how much of this would you attribute to it? The new allocation system in the US? We have seen lungs outgrowing the rest of the organs throughout 2024. And just trying to grasp the trend here as well as where we have moved in terms of EVLP penetration in the US over the year? That would be my first question, please.
Thank you.
Thank you for that question, Ulrik. Um, I will answer it. I would say we are now at an inflection point when it comes to EVLP. The interest is very high. And I would say the new allocation system is only one part of the pressure the US Congress put on the transplant system in the US. That is very positive for us. So we see that we are at an inflection point. And there are a couple of factors that coexist and help us here. One factor is that the results from EVLP are now accepted as a tool that can increase the number of transplants in a transplant center. We also reached a point where there are enough clinics accustomed to actually performing EVLP and understanding how to interpret the data. So the more standardized the reading of the data becomes, the easier it is to make a decision. And we now see that we have reached that point. So it's a couple of factors co-existing that lead to good market sentiment and a strong uptake for the ISPs in the United States right now. I don't have the exact numbers right now on where we are regarding penetration in the US, but it's definitely increasing because lung perfusion is growing at a rate more than ten times the underlying market growth.
I can provide some details on that. So, you have around 2,500 lung transplants in the US year to date. And if you look at the number of EVLPs that we have made available by selling, that's around 500. So it means, from that perspective, we have achieved a penetration of 20%. Not all of those sales have of course resulted in a transplant in the end, but that at least provides some guidance on that. We are definitely seeing the market penetration picking up in the US.
Okay. So essentially, based on the clinical data and the experts on EVLP, that number could easily double in the next five years.
It's always hard to predict the future because it's the future. But the market sentiment we feel right now is very positive. That's as much as we know. Then it will depend a lot on us how many feet we can put on the ground, how well trained they are, how fast we can get new clinics up and running, etc. . So. So we definitely have to run very fast to capture this market opportunity. We see in front of us.
Yeah. Great. And since you mentioned feet on the ground and you also mentioned in the report increased commercial activity in the US and emphasizing expansion in Canada by Q4. Can you elaborate on what this entails, what investments were made in Q3, and what is planned for Q4? I know that you hired Mark during Q3, but beyond that, what type of commercial activities have been scaled up, or what's in the plans for the next quarter or two?
Uh, we will.
We will emphasize a lot of our investments around the United States and Canada in the next year. We are currently hiring a skilled marketing team. We are scaling up our presence on the ground in the United States. And we are starting to hire our first person in Canada. I would say we have had a successful MDSAP audit, which will enable us to apply for market approval. But Health Canada, of course, is the authority granting market approval or not. So we don't have approval to sell in Canada yet, but we will start investing in Canada already in Q4. And then I will come back during the next quarterly meeting to discuss how that investment is progressing and turning into sales. But, the North American team spent a week in Canada last week, and they reported back to me that there is a very high interest in our products in Canada as we speak. And they especially mentioned the Liver Assist and the extremely good results they have seen from Europe, where you can prove in a real-life setting when everybody is tired and working, and it is not a controlled environment, then we can demonstrate such extremely good improvements for livers using our technology. I think that has inspired a lot of interest from the regions where it is or can be regulatory approved pretty soon.
Okay, great.
And if we were to consider transport logistics and operations within the US, I understand that you're ramping up production. I know there's still some production capacity left before you can deliver on OPO contracts. But beyond purely production capacity, is there any further sort of adoption to the system that you feel is needed for it to go wide in the US? And you mentioned additional trials in the US; could you elaborate on the necessity of these trials and whether there's any major difference between the dynamics of a kidney in the US versus Europe?
There is no real difference between kidneys in Europe and the US. However, the. That's not how the world works. So a US clinician wants to see data based on a US open system and US patients to adopt that. They also want to see socioeconomic data demonstrating that we can actually get more kidneys allocated with our transport method. . So that's what we are building up. We had two very good presentations during seminars in this quarter or last quarter, Q3. So, we are acquiring that body of data now, but we also realize that this will take some time to both design and actually run trials, and get the data presented. Um, so that's one thing. We have a few minor tweaks to make to the Kidney Assist transport to fit it into the US transplant system, which we will work on during this year and also part of next year. And then, we will also scale up our commercial capabilities in the US towards launching this product. I believe the team is doing a great job. But I think there are definitely a few learnings here to be really successful. Um, because this is the first quarter that could actually go out and sell the product, and we saw some good early signs. But, I think we can be much better at selling the kidney in the US as well, with training and more experience. There are a few steps still to be done, and it's something we work very hard on internally, something I'll follow up on a weekly basis. Our progress on kidney, especially in the US.
Great.
Um, if we continue in the US, we are nearing the completion of the heart trial, and it seems like it has been operating at full capacity, almost a year in, and we are nearly finished. So what's the plan here from Q1 onwards? Where are we in terms of planning for the eating trials? Is there any potential for pediatric use, or how should we expect continued use among the already activated sites?
That's a great question. And that's something we're working on together with the FDA as we speak. The interest is very high for acquiring more data around pediatric DCD, etc. The interest is extremely high. So we will pursue those efforts, and also aim to have a continuous access protocol for the trial sites. We will also pursue those avenues, let's say. And we are in negotiation with the FDA right now, and we will come back when we have more to report on that, or let's say, when the FDA has approved those efforts. But I believe and hope they will because the pressure from clinicians in the US is pretty high to use our product as they are overwhelmed with the good results. They see outstanding results when using it on the cardiac side compared to what is available today in the US. So it's an overwhelming experience for them. So I believe that we will hopefully have some positive news to come back. But right now we are in discussions and negotiations with the FDA, and it's, of course, pending their approval, what we can and cannot do on US soil.
Great. And last question on my end relating to the heart and commercialization here in Europe. That is coming up soon. Um, can you give us some timeline on expected reimbursement of the heart device? I'm guessing it will take at least half a year or a year before you get reimbursement. And how will clinics across Europe be able to find some cost coverage for the device?
Yeah, that's a good question. And there are almost as many answers as there are countries in Europe for that. Um, there will be differences country by country. Some will be quicker and some will be slower. The typical example is that France is normally quite quick. And we estimate that the reimbursement process for IBM is approximately a year there in France. We've seen that on Yelp, for example, where France was the quickest one. Also, Benelux, or at least the Netherlands, is quite quick. We know that the UK is normally quite slow, so to speak. Germany is also normally quite slow, but we have received some positive feedback from Germany now, so we might put that one on the front burner. Before we have reimbursement, there will be separate budgets for arguments to use this technology for a subset of hearts in their transplant programs, country by country. It will look a little bit different country by country; in some countries, there is more money available for new technology than in others, so to say. Um, so we will focus our European launch on a few. We will launch in 3 to 4 European countries in the first year to avoid spreading ourselves too thin. We will prioritize countries with more financial support in the healthcare system, initially focusing there until we have a clearer view of the reimbursement landscape.
Great.
Thank you for taking all my questions. Um, and I'll get back into the queue.
Thank you. Rick.
The next question comes from Jacob Lemka from Seb. Please go ahead.
Hi. Good afternoon. Starting with abdominal and zooming in. Oliver, here in Q3. It seems like growth. Uh, it decelerated a bit compared to recent quarters. Is there anything behind this other than the summer effect?
To our knowledge, no. We had a very slow summer on ABDOMINAL. It's mainly explained by southern Europe, where, to be truly honest, we observed very slow liver and kidney activities. So, abdominal activity in Europe. We can see early signs that it is picking up now, from mid-September and onwards. Now in October. Uh, so we of course have to see a full Q4 and maybe a bit into Q1 to fully answer that question. Uh, but what I heard from the sales team was that it was a very, very slow summer, so to speak. They were surprised themselves by how slow it was. And we hope that the early signs we see now in the last 4 to 5 weeks will continue into the rest of the quarter.
Okay. And just a follow-up on earlier questions about kidney. Is it possible to get some sort of guidance on what growth expectations we should have here in Q4 and also into next year?
I'm currently meeting with both the US and European teams to define the necessary activities, and we expect to complete this exercise by mid-November. After that, I will have a clearer understanding of what to expect and will be able to provide more accurate guidance than I can at this moment. So I have to wait. Maybe we can take that question in January, and I will have a better picture.
Okay, but it is still fair to assume that it should grow here. Uh, since you are able to produce more now. Or how should you think?
Absolutely. I mean, to be truly honest, there is no excuse if we don't achieve rapid growth in kidney. Absolutely. I mean, we know we have a couple of hurdles, especially in the US, when it comes to clinical data acquired on US soil. And you know, scaling up and getting the feet on the ground. Get them ready. So definitely there are a couple of challenges here, but yeah, this is not the growth rate we want to see from kidney with full-scale production or enough production, so to speak, to satisfy current demand; we want to see higher growth rates.
Okay. And moving on then to a question more directed online. Uh, I mean, last year you mentioned that transplant activities tended to slow down towards the end of the year. And I guess my question is, then, based on what you're seeing now and what you're hearing from customers, do you expect to see a similar pattern this year, or do you expect to see more, you know, full throttle throughout the end of the year?
The answer is very straightforward. We don't expect to see the same slowdown we saw last year. Um, however, Q4 is always tricky because it depends on a few factors. And what happened last year was that OPTN had a goal, which they had already realized. They have reached that one in, uh, already after Q3, and I assume a little bit of guessing from my side that a few of the centers took a little bit longer, uh, Thanksgiving and Christmas holiday, when they could actually still reach the goals. I know that OPTN has a higher goal this year, and therefore I don't expect the same downturn, at least not for the same reason. Um, and we haven't seen any signs of slowdown so far. Versus the activity that we have seen. Uh, but it's not until we get into, let's say, the holiday seasons here in the United States, that we will have a better picture on that one, but we don't expect it. But Q4 is always tricky in that sense. You never really know.
Okay. But I guess then it's still fair to assume that we see the sort of usual historical sales pattern with Q4 being the clearly strongest quarter for you.
That's our expectation right now; historically, last year was a bit of an outlier in terms of Q4. Um, the other 11 years I worked here have. Q4 has historically been the strongest. But, uh.
Yes.
Hard to speculate on that one. But, if we follow the normal pattern, it should be stronger. Yes.
Okay. And then, regarding services, given the sequential decline in volumes in Q3, I'm wondering if you have lost any customers. And also, when do you expect services to sort of return to meaningful growth?
Yes.
We touched upon this at the beginning of the year, mentioning in one of the calls that we lost two high-volume customers in 2023. And we still suffer from that loss. So to say, um. The reason for the decline this quarter was due to lower volumes at the current centers over the summer months. Um, and you know, it's not just that we have a few customers. And if a few of them decrease their volumes. There is an impact on the numbers. Um, same thing here. As for the kidney sector, we have all the reasons to expect this business to grow. We have an excellent platform built and we're strengthening it now, as you mentioned, with FlowHawk. We continue to improve our communication and integration with our customers. So, we should expect an increase. However, I would say that the inflection point here and the real booster will be when we have a transportable device to combine with our service offering, and that is the hot box. So that this one, I think the real synergies will come from this long-term strategic acquisition that we did.
Okay.
Very clear. And then, just to clarify, it was a bit unclear earlier, but did you mention that you will obtain continued access protocol on hardware, or are you in the process of securing that? And also, if you get that, what sort of volumes would that be like? Would it be in line with what you do today in the study, or would anything else be helpful?
Uh, hard to speculate on the volume. Of course, we have not approved that. We are in negotiation with the FDA, but if we follow the history of how the FDA has treated other trials such as ours, they have granted continuous access protocol. The volume or the number of cases they have granted has typically been three quarters of the trial volume. So, that's the best estimate I can give today. Um.
Okay.
That's very clear.
Good. Thank you very much. That's all for me today.
Thank you. Thank you.
The next question comes from Johan Aeneas from Redeye. Please go ahead.
Thanks for taking our questions. Thanks for taking our questions. Only a few questions, mainly of the follow-up type. On the heart study and the centers involved. It looks hopeful that you will succeed in establishing continuous access support. The FDA has been very supportive and rather proactive earlier. On this side for you. No, no, absolutely.
No, no, absolutely. There's no reason. It's just that dealing with the FDA. The FDA, as you might say, sets the rules. I'm always very humble and cautious when I talk about the FDA because, at the end of the day, they decide. I have no reason to believe that we should not get a positive treatment, so to say. Uh, but it's always good to be humbled and make sure you do your homework when you're dealing with the FDA.
Yes. And you are benefiting from some sales support related to the use of your solutions already at the trial stage. Is it possible to provide an idea of the level of support, for example, during Q3?
Uh, you mean in terms of numbers? Yes. We won't, no, we won't release detailed numbers during the trial, but we know that the cost recovery is $32,000 USD. And we know that the majority of heart sales came from the US in Q3, but we won't disclose detailed figures because it's a clinical trial. We won't disclose exact numbers. How many were performed in each quarter? There is a high level of, let's say, patient safety that we should keep in mind. We should keep in mind the high level of patient safety. So we don't comment exactly on the trial, but we do see very good progress during the third quarter.
Yeah. That's useful. And on the services side, which is obviously underperforming now for some quarters. Should we expect any sort of organizational changes or anything like that? And what about providing some insights into the pipeline of new accounts or transactions?
Yeah. Um, so I would say organizational. Overall, we are strengthening and will continue to strengthen our US organization. And with Mark Read on board, we will work diligently on our US service strategy, which will be a high priority for us in 2025. But, I mean, the foundation is there, with excellent, skilled surgeons; we turned this company profitable last year. That was the main purpose in terms of customers. Yes. I mean, there is a pipeline we're working on, and we will also look into other types of services as well. It's early days, but we know that there is a significant interest in perfusion services at hospitals as well. That's one thing we will look into; for example, as we have mentioned before, we have started one or two pilot projects within NRP with centers as well. So there are, you know, we need to define, maybe a bit more clearly, our strategy, but there are definitely a lot of market opportunities.
Yeah, I can just mention on that. I mean, we're not happy at all with the progress in services. And of course, we will integrate FlowHawk and during that integration, we will also try to understand what more 'feet on the ground' would do for the integrated digital and service business. , would do for the integrated, let’s say, digital and service business. So there might be more resources needed in our go-to-market model because we have a good service that is obviously not taking off. So we are doing something wrong when it comes to going to market, and we need to fix that.
Yes, I mean, it's important to mention, of course. It's important to support with integrated services, even if the absolute numbers are still modest. And another reflection is that some of these launch processes take a bit longer to get up to speed, and Q3 is perhaps a good example of how you can still achieve very good growth, very good growth indeed. But you will also be more sort of exposed to and rely on, rely on, some of the core existing solutions like lung and thorax. What about the outlook? Can you expect reasonably good support during this time ahead of the launch of other solutions?
I mean, we are at an interesting inflection point as a company where we have, of course, succeeded with perfect performance. And now we have succeeded with ERP. And now we want to take those learnings to succeed in heart transplants in Europe. And for the liver, we aim to apply these learnings to our combined digital service offering in the US and to the launch of our kidney assist transport here in the US. So definitely, there is an interesting point where we have to be fast and learn fast. Definitely, it's there. I don’t want to be rude, but we have another meeting right now. Both Christopher and I see there are two written questions. I will read them and answer them. The first one is, could you give some more color on the possible Canadian launch? Is that based on US data or EU data? The Canadian launch will be based on European regulatory approvals and therefore mainly European data to answer that question. The next question is, um. In short, has there been any notable slowdown in volume so far this quarter due to the recent hurricanes that hit the United States, especially in the southern regions around Florida, Georgia, and South Carolina? And to my knowledge, there have been a few cancellations of transplants because you can't fly in a hurricane. But so far, there has been no huge impact on the overall numbers of transplants in the United States, to my knowledge. So with that, I want to say thank you to everyone listening in. And, I hope to see you back at the end of January when we report the full year of 2024. And until then, have a nice day.



















